Covington, Latham Craft UCB's Zogenix Buy Of Up To $1.9B
Belgium-based biotechnology company UCB has agreed to buy California rare disease focused drugmaker Zogenix for up to $1.9 billion, the companies said Wednesday, in a deal stitched together by respective legal...To view the full article, register now.
Already a subscriber? Click here to view full article